Galush William J, Wakankar Aditya A
Early Stage Pharmaceutical Development, Genentech Inc., South San Francisco, CA, USA.
Methods Mol Biol. 2013;1045:217-33. doi: 10.1007/978-1-62703-541-5_13.
Formulation development of an ADC resembles that of a conventional antibody, but the conjugated form introduces new molecular attributes such as drug-to-antibody ratio and stability of the drug itself that need to be considered. An extended set of analytical tools, coupled with understanding of how ADCs and conventional antibodies differ in terms of their stability, guides formulation selection.
